What were the long‑term outcomes of the LIRIC (LIR!C) trial comparing laparoscopic ileocaecal resection versus infliximab therapy in adult patients with non‑stricturing, immunomodulator‑refractory ileocaecal Crohn’s disease?

LIRIC Trial Long-Term Outcomes

Laparoscopic ileocaecal resection demonstrates superior 10-year therapy-free remission (35.8% vs 13.2%) compared to infliximab in patients with limited, non-stricturing ileocaecal Crohn's disease, with particularly strong benefits in younger patients. 1

Primary Trial Results (12-Month Outcomes)

The original LIRIC trial randomized 143 patients with active, non-stricturing ileocaecal Crohn's disease (<40 cm terminal ileum involvement) who failed conventional therapy (≥3 months of corticosteroids, thiopurines, or methotrexate) to either laparoscopic ileocaecal resection (n=73) or infliximab (n=70). 2

Quality of life outcomes at 12 months were equivalent between groups:

• Primary endpoint (IBDQ score): 178.1 (resection) vs 172.0 (infliximab), difference 6.1 points (95% CI -4.2 to 16.4; p=0.25) 2
• SF-36 physical component: 47.7 vs 44.6, favoring resection by 3.1 points (p<0.05) 2
• SF-36 mental component: 49.5 vs 46.1, difference 3.5 points (not significant) 2

Safety profile was comparable:

• Serious complications (Clavien-Dindo ≥IIIa): 4 patients in resection group 2
• Treatment-related serious adverse events: 2 patients in infliximab group 2

Extended Follow-Up Data (Median 4-6 Years)

At median 63.5 months follow-up (134/143 patients, 94% retention): 3

Treatment crossover rates:

• 26% (18/69) of resection patients required anti-TNF therapy 3
• 48% (31/65) of infliximab patients required surgical resection 3
• 42% of resection patients required no additional Crohn's disease medication (though 48% of these received prophylactic immunomodulators) 3

Duration of treatment effect was similar:

• Median time without additional therapy: 33.0 months (resection) vs 34.0 months (infliximab), p=0.52 3
• Concomitant immunomodulator use significantly extended treatment effect in both groups (HR 0.34 for resection, HR 0.49 for infliximab) 3

10-Year Outcomes (Definitive Long-Term Data)

The most recent 10-year follow-up (129/143 patients, 90% retention; median follow-up 11 years) provides the strongest evidence for clinical decision-making: 1

Therapy-free remission at 10 years (primary outcome):

• 35.8% (resection) vs 13.2% (infliximab), difference 22.6% (95% CI 7.8-36.8; p=0.0038) 1
• This represents a nearly 3-fold advantage for surgical resection

Overall clinical remission at 10 years:

• 36.5% (resection) vs 28.4% (infliximab), HR 0.79 (95% CI 0.52-1.20; p=0.27) 1
• While not statistically significant overall, exploratory analyses revealed critical age-dependent effects

Age-dependent treatment effects (post-hoc analysis):

• For 20-year-old patients: 54% clinical remission (resection) vs 24% (infliximab), difference 30% (95% CI 7-53) 1
• For 30-year-old patients: 38% (resection) vs 28% (infliximab), difference 10% (95% CI -6 to 26) 1
• Interaction p-value = 0.020, indicating younger patients derive substantially greater benefit from resection 1

Cost-Effectiveness Analysis

Laparoscopic resection demonstrated clear economic advantages: 4

• Mean Crohn's disease direct healthcare costs lower by €8,931 (95% CI €5,097-€12,087) 4
• Total societal costs lower by €5,729 (95% CI -€172 to €10,606) 4
• Probability of cost-effectiveness: 96% at €0/QALY, increasing to 98% at €20,000/QALY 4
• Note: These calculations used originator infliximab pricing; biosimilar availability may narrow but not eliminate this advantage 5

Guideline Integration

The ECCO 2020 guidelines explicitly incorporated LIRIC findings: "Laparoscopic resection in patients with limited, non-stricturing, ileocaecal Crohn's disease [diseased terminal ileum <40 cm] is a reasonable alternative to infliximab therapy." 6

The BSG 2019 guidelines recommend: "Laparoscopic resection should be considered in localised ileocaecal Crohn's disease for those failing or relapsing after initial medical therapy, or in those preferring surgery to continuation of drug therapy." 5

The BSG 2025 guidelines emphasize quality of life as a formal treatment target, citing LIRIC as exemplifying patient-centered outcome assessment beyond traditional inflammatory markers. 7

Clinical Application Algorithm

Consider laparoscopic ileocaecal resection as first-line escalation therapy when:

• Terminal ileum involvement <40 cm
• Non-stricturing, non-penetrating disease
• Failed ≥3 months conventional therapy (corticosteroids, thiopurines, or methotrexate)
• No previous resection
• No abdominal abscesses
• No pre-stenotic dilatation requiring urgent surgery
• Especially if patient age <30 years (based on age-dependent benefit) 1

Infliximab remains appropriate when:

• Patient preference for medical management
• Surgical contraindications exist
• Extensive disease (>40 cm)
• Multiple previous resections
• Perianal fistulizing disease requiring anti-TNF

Critical Caveats

Trial exclusion criteria limit generalizability:

• Previous resection excluded 2
• Stricturing disease with pre-stenotic dilatation excluded 2
• Abdominal abscesses excluded 2

Post-operative prophylaxis considerations:

• 48% of medication-free resection patients received prophylactic immunomodulators 3
• Concomitant immunomodulator use significantly improved outcomes in both groups 3
• Current guidelines recommend considering postoperative prophylaxis based on risk factors 5, 7

The age-dependent effect requires validation but suggests younger patients (particularly <25 years) should be counseled about potentially superior long-term outcomes with early surgical intervention rather than prolonged medical escalation. 1